Corneal Endothelial Cell Loss in Glaucoma and Glaucoma Surgery and the Utility of Management with Descemet Membrane Endothelial Keratoplasty (DMEK). (30th January 2022)

• Record Type: Journal Article
• Authors: Vallabh, Neeru A; Kennedy, Stephnie; Vinciguerra, Riccardo; McLean, Keri; Levis, Hannah; Borroni, Davide; Romano, Vito; Willoughby, Colin E
• Other Names: Yesilirmak Nilufer Academic Editor.
• Is Part Of: Journal of ophthalmology. Volume 2022(2022)
• Publication Date: 2022-01-30
• Subjects: Ophthalmology -- Periodicals; Eye Diseases; Ophthalmology; Ophthalmology; Electronic journals; Periodicals; Periodicals; Fulltext; Internet Resources; Periodicals; 617.7
• DOI: 10.1155/2022/1315299
• Languages: English
• ISSNs: 2090-004X

Abstract

Abstract : The corneal endothelium has a crucial role in maintaining a clear and healthy cornea. Corneal endothelial cell loss occurs naturally with age; however, a diagnosis of glaucoma and surgical intervention for glaucoma can exacerbate a decline in cell number and impairment in morphology. In glaucoma, the mechanisms for this are not well understood and this accelerated cell loss can result in corneal decompensation. Given the high prevalence of glaucoma worldwide, this review aims to explore the abnormalities observed in the corneal endothelium in differing glaucoma phenotypes and glaucoma therapies (medical or surgical including with new generation microinvasive glaucoma surgeries). Descemet membrane endothelial keratoplasty (DMEK) is increasingly being used to manage corneal endothelial failure for glaucoma patients and we aim to review the recent literature evaluating the use of this technique in this clinical scenario.